Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Current Target Price: $1040 Joseph Bonner, CFA -- Netflix has developed from upstart Hollywood outsider to being the central player in long-form streaming video, what has now become the future of the ...

HBW Advisory Services LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 2.7% during the 4th quarter, according to its most recent disclosure with the SEC. The ...

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...